tbuckley/cabot-search huggingface dataset:
An innocent thrill. A common finding with an innocent murmur
Authors: W. Bujack
Journal: JAMA (1976)

A THRILL is usually considered to be pathognomonic of an organic heart lesion; however, during the past 18 years one of the authors (G.G.C.) has examined more than 500 children who had innocent thrills associated with venous hums. Because a thrill associated with a venous hum had never been reported, the first five patients examined by G.G.C. were suspected of having arterial venous fistulae and consequently these five patients had complete cardiac catheterization and angiographic studies that were entirely normal. The purpose of this communication is to report the incidence of an "innocent" thrill associated with venous hum. During October and November 1975, 100 consecutive children with venous hum (from 2 to 15 years of age) were examined carefully for the presence of a thrill. The Table lists the incidence of thrill in these 100 patients and also lists the number of patients according to age and sex. Thus, a
Sarcopenia increases the risk of post transjuglar intrahepatic portosystemic shunt hepatic encephalopathy
Authors: Puja Bhatia Kapoor, Harshita Tripathi, Jaya Benjamin, Rakhi Maiwall, Yashwant Patidar, Shalini Thapar, Dr. Puneet Puri, Guresh Kumar, Yogendrakumar Joshi, Shiv Kumar Sarin
Journal: Journal of Hepatology (2020)
The epiphyses and the childhood athlete
Authors: R. L. Larson
Journal: JAMA (1966)

There have been objections raised to the participation of children 9 to 15 years old in athletics. These have been gendered by the fear of epiphyseal injury and permanent deformity. A review of 1,338 consecutive athletic injuries seen by four orthopedists revealed that 20% occurred in the age group 14 years old and younger. Of injuries occurring in the age group 15 years old and younger 6% were epiphyseal. Because the epiphyseal-metaphyseal junction is less strong than the fibrous and ligamentous supports around joints, injuries to such joints must be checked for possible epiphyseal injury. Roentgenographic evaluation combined with clinical judgment is necessary to detect epiphyseal injury.
REMARKS ON INSANITY.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CRYSTALLINE INSULIN
Authors: JOSEPH H.  BARACH
Journal: Annals of Internal Medicine (1937)

Article1 March 1937CRYSTALLINE INSULINJOSEPH H. BARACH, F.A.C.P.JOSEPH H. BARACH, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-10-9-1335 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is now 14 years since insulin was made available to the medical profession and the results of a vast experience with its effects are now at hand. About two years ago, a modified insulin, protamine insulin, was offered to the medical profession. One of the most interesting revelations that came with this new insulin was the limitations of the old insulin. When reports began coming in on the new insulin, we came to realize how many insulin-treated diabetics in the hands of highly experienced workers were not under good control at all. This admission should have its sobering influence...Bibliography1. HAGEDORNJENSENKRARUPWODSTRUP HCBNNBI: Protamine insulinate, Jr. Am. Med. Assoc., 1936, cvi, 177. CrossrefGoogle Scholar2. ROOTWHITEMARBLESTOTZ HFPAEH: Clinical experience with protamine insulinate, Jr. Am. Med. Assoc., 1936, cvi, 180. CrossrefGoogle Scholar3. SPRAGUEBLUMOSTERBERGKEPLERWILDER RGBBAEEJRM: Clinical observations with insulin protamine compound, Jr. Am. Med. Assoc., 1936, cvi, 1701. CrossrefGoogle Scholar4. ALLEN FM: Some difficulties arising in the use of protamine insulinate, Jr. Am. Med. Assoc., 1936, cvii, 6. Google Scholar5. WILDER RM: Clinical investigations with insulin protamine compound, Proc. Staff Meet. Mayo Clinic, 1936, ii, 17. Google Scholar6. LAWRENCEARCHER RDN: Some experiments with protamine insulinate, Brit. Med. Jr., 1936, i, 747. CrossrefGoogle Scholar7. JOSLINROOTMARBLEWHITEJOSLINLYNCH EPHFAPAPGM: Protamine insulin, New Eng. Jr. Med., May 28, 1936. Google Scholar8. FREUNDADLER HAS: Effects of standard, protamine and crystalline insulin on blood sugar levels, Jr. Am. Med. Assoc., 1936, cvii, 573. CrossrefGoogle Scholar9. MAINSMCMULLIN PMCJ: The clinical investigation of an improved crystalline insulin, Jr. Am. Med. Assoc., 1936, cvii, 959. CrossrefGoogle Scholar10. BARACH JH: Lower fat diet in diabetes, Am. Jr. Dig. Dis. and Nutr., 1934, i, 124. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Pittsburgh, Pennsylvania*Received for publication October 8, 1936. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClinical Experience With Crystalline Insulin 1 March 1937Volume 10, Issue 9Page: 1335-1344KeywordsInsulinProtamines ePublished: 1 December 2008 Issue Published: 1 March 1937 PDF downloadLoading ...
Involvement of the practicing physician in the training of students: the Illinois experience
Authors: T. E. Gamble
Journal: JAMA (1973)

The practicing phyician has long been a welcome participant in the training of medical students. Since World War II, however, his influence in medical education has diminished. A study at the University of Illinois College of Medicine was made with 20 practicing physicians who have returned to the fore in medical education in an innovative experiment in the remarriage of practice with theory. The physicians are involved in the University of Illinois School of Basic Medical Sciences at Urbana-Champaign (SBMS-UC) as nonsalaried clinical faculty from the east central Illinois region. Their task is to act as advisers, tutors, evaluators, and friends to the students. The School of Basic Medical Sciences has an innovative program that approaches the basic sciences through a series of clinical problems. From the very beginning, the student is exposed to clinical practice, hospital routine, and laboratory techniques and findings through his physician-adviser. The adviser and student
HIV Prevention Programs Should Address Dual Risk Factors in Men
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply:
Authors: Christopher G. Azzoli, David G. Pfister, David H. Johnson, Mark R. Somerfield
Journal: Journal of Clinical Oncology (2004)

was compared with single agents, no significant difference was found for any outcome.Survival curves of treatments scattered by PS are depicted in Figure 1.Testing the interaction between PS and treatments on survival in a Cox regression model, adjusting by size of center, age, sex, stage, histotype, and major comorbidities, still yielded results that were not significant (P ϭ .35for GEMVIN v vinorelbine and P ϭ .34 for GEMVIN v gemcitabine).These data confirm the lack of effectiveness of combination chemotherapy with gemcitabine and vinorelbine versus each single agent in the subgroup of PS 2 patients.All treatments studied were substantially well tolerated in PS 2 patients as well as in PS 0 to 1 patients; however, the overall survival was significantly shorter in PS 2 patients.In our opinion, this is a further warning regarding the role of chemotherapy and the need of new therapeutic strategies for unfit patients. 3 At present, single-agent chemotherapy with drugs characterized by a low toxicity profile should remain the standard treatment for PS 2 patients. 4 Consequently, single-agent chemotherapy should be the standard arm against which experimental treatments should be tested in randomized clinical trials dedicated to PS 2 patients.
REPORT OF THE WOMAN'S AUXILIARY
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Revista de Otorrinolaringología, Santiago
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Le Sympathique et Les Systèmes Associés: Anatomie Clinique, Sémiologie et Pathologie Générale du Système Neuro-Glandulaire de la Vie Organique.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pneumocystis carinii pneumonia in a hospital for children. Epidemiologic aspects
Authors: D. R. Perera
Journal: JAMA (1970)

<i>The first large outbreak of</i>Pneumocystis carinii<i>pneumonia reported in the United States occurred at St. Jude Children's Research Hospital in Memphis. Seventeen cases were documented during 1968 through 1969; only two cases had been identified in the preceding six years. All 19 affected children were being given immunosuppressive drugs for malignant disease; 14 had acute leukemia. A review of 301 consecutive autopsies at St. Jude demonstrated clinically inapparent</i>P carinii<i>infection in 40 additional patients. Epidemiologic analysis suggested that more intensive chemotherapy caused the outbreak of</i>Pneumocystis<i>pneumonia by activating the inapparent</i>Pneumocystis<i>infection commonly associated with neoplastic disease</i>.
Estimated Influenza Vaccination Coverage Among Adults and Children—United States, September 1, 2004–January 31, 2005
Journal: JAMA (2005)

In response to the unexpected shortfall in the 2004--05 influenza vaccine supply, CDC recommended in October 2004 that vaccine be reserved for persons in certain priority groups, including persons aged > or =65 years and 6--23 months, persons aged 2-64 years with conditions that increased their risk for influenza complications, residents of chronic-care facilities, close contacts of infants aged <6 months, and health-care workers with direct patient contact. In late December 2004, based on declining demand among these groups, two additional groups (i.e., healthy persons aged 50-64 years and household contacts of all persons at high risk) were added to the list of vaccination priority groups. To monitor influenza vaccination coverage during the 2004-05 season, the Behavioral Risk Factor Surveillance System (BRFSS), an ongoing, state-based, telephone survey of civilian, noninstitutionalized persons, added new questions to collect information on priority status and the month and year of vaccination for adults and children. This report is based on analysis of data collected during February 1-27, 2005, regarding respondent-reported receipt of influenza vaccination during September 1, 2004-January 31, 2005. The results of this analysis indicated that influenza vaccination coverage levels through January 2005 among adults in priority groups nearly reached those in recent years, whereas coverage levels among adults not in priority groups were approximately half of levels in 2003, in part because 9.3% of those unvaccinated persons in nonpriority groups declined vaccination this season. The results further suggested that designation of the priority groups successfully directed the nation's influenza vaccine supply to those at highest risk. In addition, vaccination coverage among children aged 6-23 months was notable (48.4%), given that 2004-05 was the first year this group was recommended for influenza vaccination .
The Complete Book of Diets for All Ages, Including Medical Dietetic Suggestions for 325 Common Ailments
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1590: Sulfasalazine sensitizes glioblastoma cells to radiation treatment.
Authors: Linda Sleire, Bente S. Skeie, Inger A. Netland, Jan Heggdal, Paal-Henning Pedersen, Per Ø. Enger
Journal: Cancer Research (2013)

Abstract Glioblastoma (GBM) is a lethal cancer with a limited response to ionizing radiation. Recent studies suggest that Sulfasalazine (SAS), a drug used to treat inflammatory bowel disease, inhibits the Xc− antiporter system in glioma cells, thereby blocking their uptake of cystein. Since the availability of cystein is a rate limiting step in intracellular antioxidant production, we wanted to investigate whether sulfasalazine sensitizes glioma cells to radiation. Expression of xCT, the catalytic subunit of system Xc−, was found in 30 patient GBM biopsies. SAS effect on glioma cell growth was investigated using an electric cell substrate impedance sensing (ECIS) instrument. All glioma cell lines showed altered growth curves in response to SAS treatment. To assess the effect of blocking the antiporter, intracellular levels of the antioxidant glutathione were measured. With increasing doses of SAS, glutathione levels decreased in a dose response manner. In addition, cysteine was added to the medium to see if the toxic effects of SAS could be counteracted. Furthermore, accumulation of reactive oxygen species upon SAS treatment was measured. Glioma cells were also treated with escalating doses of SAS, alone or in combination with radiation (8 Gy). The presence of double stranded breaks increased markedly in the irradiated samples and also somewhat with increasing doses with SAS. In addition, cell death, viability and clonogenicity were investigated using live/dead staining, the MTS assay and the clonogenic assay. All treatment groups exhibited increased rates of cell death compared to untreated controls. A combination of SAS and radiation resulted in higher levels of cell death, than radiation or SAS administered alone. Furthermore we continued with implantation of human GBMs into the brain of Nude rats. These animals were treated with Gamma Knife Radiosurgery alone or in combination with SAS. SAS were administered as a pre-treatment for three days before Radiosurgery. The rats receiving the combination treatment lived significantly longer compared to either treatment alone. Interestingly, the animals only receiving pre-treatment with SAS for three days lived significantly longer compared to the untreated controls, although this was not statistically significant. We are currently preparing a clinical trial for patients with GBM recurrences combining pre-treatment with Sulfasalazine and Gamma Knife Radiosurgery. Citation Format: Linda Sleire, Bente S. Skeie, Inger A. Netland, Jan Heggdal, Paal-Henning Pedersen, Per Ø. Enger. Sulfasalazine sensitizes glioblastoma cells to radiation treatment. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1590. doi:10.1158/1538-7445.AM2013-1590
Premature ventricular complexes. Diagnosis and indications for therapy
Authors: J. Morganroth
Journal: JAMA (1984)

APPROXIMATELY every minute in the United States, one person dies of sudden cardiac death. This accounts for more than one half of all deaths due to coronary artery disease, a disease that also commonly displays the syndromes of angina pectoris and acute myocardial infarction. Of the approximately 1.25 million Americans who have an acute myocardial infarction per year, more than one half die before reaching a medical facility, and of those who survive hospitalization, approximately 10% or more will be dead in the first year. Half of this mortality will be caused by sudden cardiac death. Sudden cardiac death is the leading cause of death in the 20- to 64-year-old age range and has the most dramatic social, psychological, and economical impact of any disease, particularly since it occurs prematurely in life, usually without warning or clear precipitating factor. Studies in individuals who have sudden cardiac death while fortuitously wearing
Mycoplasma pneumoniae pneumonia and clindamycin therapy. Failure to demonstrate efficacy
Authors: J. D. Smilack
Journal: JAMA (1974)

A double-blind study was undertaken to evaluate the efficacy of clindamycin hydrochloride hydrate as compared with tetracycline hydrochloride and placebo in the treatment of<i>Mycoplasma pneumoniae</i>. Thirty-two young adult men were studied. Clindamycin failed to cause defervescence or roentgenographic resolution more promptly than placebo. Tetracycline was associated with a shortening of the duration of fever. (<i>JAMA</i>228:729-731, 1974)
TCTAP A-082 Impact of Lipid Rich Plaque at the Stent Edge Assessed by Optical Coherence Tomography on Edge Restenosis After EES Implantation
Authors: Yasushi Ino, Takashi Kubo, Keisuke Satogami, Tomoko Nakamura, Aiko Shimokado, Yasutsugu Shiono, Makoto Orii, Yoshiki Matsuo, Tomoyuki Yamaguchi, Takashi Yamano, Atsushi Tanaka, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2015)